Harvard’s R&D alliance with Resilience to advance manufacture of complex medicines – Harvard Gazette
stemadminStem Cell ResearchNo comments

Harvard University and National Resilience, Inc. (Resilience), a manufacturing and technology company, have established a five-year R&D alliance with a $30 million commitment from Resilience directed toward the development of complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies. Under the alliance agreement coordinated by Harvards Office of Technology Development (OTD), Resilience will fund faculty-initiated research focused on certain novel therapeutic and biomanufacturing technologies pioneered in University labs.

Read more
Molecular Atlas of Small Cell Lung Cancer Reveals Unusual Cell Type That Could Explain Why Its So Aggressive – On Cancer – Memorial Sloan Kettering
stemadminStem Cell ResearchNo comments

Imagine youre about to go on a cross-country trip, stopping at spots along the way to admire local attractions. Youd probably want to have a road atlas handy, containing maps at different scales, covering both the major highways and the roads of smaller cities and towns or at least a GPS that can access a digital atlas with this information. Until recently, cancer researchers have been like cross-country travelers with only a few maps of a few popular cities.

Read more
Taking aim at the brain, Takeda strikes up cell therapy R&D alliance with Immusoft – MedCity News
stemadminStem Cell ResearchNo comments

The first cell therapies made from a patients own cells were cancer treatments T cells engineered to hit tumors. Immusoft is taking a similar approach with a different type of immune cell, aiming to deliver these cell therapies into the brain. The biotech startup is still preclinical, but Takeda Pharmaceutical sees enough promise to begin a research and development alliance that could yield new treatments for rare neurometabolic diseases.

Read more
Longevity Foundation to Fund Geroscience Research with 860M – Labiotech.eu
stemadminStem Cell ResearchNo comments

The newly-created Longevity Science Foundation aims to extend the human lifespan to more than 120 years by channeling over 860M ($1B) into early-stage geroscience research in the next decade. Experts say thats a worthy if complex goal. Based in Zug, Switzerland, the Longevity Science Foundation will prioritize four areas of research: personalized medicine, therapeutics, artificial intelligence (AI) and predictive diagnostics.

Read more

Theme: Illdy.